Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Compensation to top executives at private life sciences companies continued along its upward trajectory, standing in stark contrast to flat pay levels at technology firms.
Clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are surplus to requirements and may even be a barrier for the development of biosimilars of more complicated biologics.
Reviewing the major features in the patent landscape of RNA-mediated gene suppression may aid the development of patent strategies that will support the next generation of genetically modified crops.
Cloud computing offers solutions for companies wrestling with large-scale data sets, but security issues will likely continue to restrict its use to precompetitive or nonconfidential data. Clare Sansom reports.